Oncology research and development has consistently seen significant growth around the world in the past few years, but trial diversity, and especially inclusion of Black and Hispanic patients, has continued to fall behind studies in other therapeutic areas, as shown in a recent report by the IQVIA Institute for Human Data Science.
Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds
Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.
More from Clinical Trials
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
A decision from the FDA is due by 28 September.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.